Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Weekly Update for the Week Ending November 2, 2019

11/4/2019

 
Regulatory Update
 
The FDA approved diroximel fumarate (Vumerity, Biogen/Alkermes) on 10/30/2019 for the treatment of relapsing forms of multiple sclerosis. Diroximel fumarate is an oral prodrug of monomethyl fumarate, which allows the 505(b)(2) pathway based on Biogen’s dimethyl fumarate (Tecfidera) to be used. Biogen licensing diroximel fumarate from Alkermes.
 
Chugai announced that in October 2019 the FDA accepted the BLA and the EMA accepted the MAA of satralizumab for the treatment of neuromyelitis optica spectrum disorder.
 
Announced Research Updates
 
Actinium announced interim data from 75 patients in the 150 patient, Phase III, SIERRA trial, where 100% of patients treated with Iomab-B achieved successful engraftment of allogeneic hematopoietic stem cell transplant compared to 18% that received salvage chemotherapy in patients with active, relapsed or refractory acute myeloid leukemia.
 
Athenex announced that in two 57-day, Phase III trials, treatment of actinic keratosis with tirbanibulin resulted in complete clearance in 44% and 54% of the patients compared to 5% and 13% for vehicle treated groups. One-year follow-up found recurrence rates of 74% and 72% with tirbanibulin. Athenex plans to submit an NDA for tirbanibulin in 1Q21 and an MAA in 2Q21.
 
AZ announced preliminary results from the 1,000 patient, Phase III, open-label, POSEIDON trial of patients with metastatic non-small cell lung cancer with PD-L1 expression levels, but not mutation in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene. Progression free survival was improved with both durvalumab, tremelimumab and platinum-based chemotherapy and durvalumab and platinum-based chemotherapy compared to platinum-based chemotherapy alone as first line treatment
 
AZ announced that in a 26 patient, Phase II, open-label trial, treatment with selumetinib resulted in a partial response in 71% of patients with patients with neurofibromatosis type 1.
 
TG Therapeutics announced that in the 112 patient, open-label, Phase IIb, UNITY-NHL trial, treatment with umbralisib achieved the predetermined target overall response rate of 40% to 50% in patients with follicular lymphoma who have received at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent.
 
Cyclerion announce that in a 12-week, 156 patient, Phase II trial, treatment with praliciguat did not improve the urine albumin to creatinine ratio compared to placebo in patients with type 2 diabetes and diabetic nephropathy. Cyclerion also announce that in the 12-week, 196 patient, Phase II, CAPACITY trial, treatment with praliciguat did not improve cardiopulmonary exercise testing compared to placebo in heart failure patients with preserved ejection fraction. Cyclerion is discontinuing development of praliciguat for the treatment of heart failure with preserved ejection fraction and plans to license the drug to another company for development as a treatment for diabetic nephropathy.
 
Published Research Updates
 
In a 3 year, 3,289 patient, Phase IIb trial, immunization with M72/AS01E resulted in 0.3 active pulmonary tuberculosis cases per 100 person-years compared to 0.6 cases per 100 person-years with placebo in African patients with withlatent Mycobacterium tuberculosis infection. M72/AS01E's efficacy was 49.7%. 70% of the patient population had already received the BCG vaccine.
 
The 26-week interim data from a 52-week, 3 patient, Phase IIb trial, found that 26-weeks after a single infusion of etranacogene dezaparvovec resulted in a mean increase in Factor IX (FIX) activity of 47% of normal range (individual results: 33%, 51%, 57%) and no patient required a Factor IX infusion, experienced a bleeding event or required immunosuppression.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.